# Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study

Source: https://onco.cc/trials/nct07295821/  
OnCo record `nct07295821` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Osimertinib in advanced solid tumours, run by AstraZeneca, now recruiting.

## Summary

Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study is a phase 2 interventional study registered as NCT07295821 by AstraZeneca, with 60 participants planned, started 2026-04-01 and due to reach its primary completion in 2029-05-30. Interventions recorded: Osimertinib.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07295821
- Phase: 2
- Setting: Phase II, Single-arm Multicenter Study of Osimertinib Induction Before Radiotherapy and Maintenance in Chemo-ineligible or Refusing Patients With Stage III, Unresectable NSCLC and EGFR Mutation-positive Tumors
- Sponsor: AstraZeneca
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT07295821: https://clinicaltrials.gov/study/NCT07295821

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Osimertinib](https://onco.cc/drugs/osimertinib/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct07295821.json